GlassScriptPhysician profile
Gennaro Labella
NPI 1306953989
$13,553.67
in general payments reported to CMS, 2019-2025
19 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $319 · 2021: $3,156 · 2022: $1,503 · 2023: $396 · 2024: $7,411 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,246 · Food and Beverage: $1,190 · Travel and Lodging: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,246.00 |
| Food and Beverage | $1,189.70 |
| Travel and Lodging | $959.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $10,834.92 | 2020-2024 | Axonics |
| Steris Corporation | $1,451.83 | 2021 | |
| Boston Scientific Corporation | $176.76 | 2025 | Axonics |
| Olympus America INC. | $174.40 | 2025 | Hanarostent Esophagus Tts(Ccc), Single Use Repositionable Clip, Olympus |
| Takeda Pharmaceuticals U.S.A., INC. | $144.92 | 2020-2024 | Gattex |
| Abbvie INC. | $107.73 | 2025 | |
| Covidien LP | $107.43 | 2019 | |
| Palette Life Sciences, INC. | $98.41 | 2021 | |
| Kerecis Limited | $74.81 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $73.00 | 2022-2025 | Interstim |
| Ethicon US, LLC | $72.43 | 2019-2022 | |
| Acera Surgical, INC. | $51.92 | 2024 | Restrata Wound Matrix |
| Medtronic USA, INC. | $43.84 | 2019-2020 | |
| Braintree Laboratories, INC. | $40.65 | 2019-2020 | |
| Convatec INC. | $29.35 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $19.19 | 2025 | |
| Halozyme INC | $18.99 | 2025 | Hylenex Recombinant |
| Merck Sharp & Dohme LLC | $18.09 | 2025 | Bridion |
| Qol Medical, LLC | $15.00 | 2025 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gennaro Labella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.